Overview

Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas

Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate both enzastaurin and bevacizumab in the treatment of recurrent malignant gliomas.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Collaborator:
Genentech, Inc.
Treatments:
Anticonvulsants
Bevacizumab